Literature DB >> 22970052

Expression of keratin 20 and its clinicopathological significance in intrahepatic cholangiocarcinoma.

Ji Eun Choi1, Sang Jae Noh, Ju Hyung Lee, Jun Sang Bae, Hyun Hee Chu, Ho Sung Park, Kyu Yun Jang, Myoung Ja Chung, Myoung Jae Kang, Dong Geun Lee, Woo Sung Moon.   

Abstract

Although the expression of keratin 7 (K7) and K20 is considered to be a useful factor in the differential diagnosis of intrahepatic cholangiocarcinoma (ICC) and metastatic colorectal carcinoma (CRC) of the liver, a proportion of typical ICC retains K20 expression. The frequency and biological significance of K20 expression in ICC remains unclear. We analyzed the expression of K7, K19 and K20 in 66 surgically resected liver tumors consisting of 46 ICCs and 20 metastatic CRCs of the liver and 20 corresponding primary CRCs. In the 46 ICCs, K7, K19 and K20 were expressed in 40 (87%), 45 (98%) and 16 (35%) cases, respectively. K7, K19 and K20 were expressed in 1 (5%), 20 (100%) and 16 (80%) of the 20 primary CRCs and 2 (10%), 20 (100%) and 16 (80%) of the 20 metastatic CRCs, respectively. A combined K7/K20 profile was identified as a good predictor for differentiating ICC and metastatic CRC. K20 expression in ICC was significantly associated with male gender (P=0.034), hilar location (P=0.026), intraductal papillary type (P=0.006), intestinal phenotype (P<0.001) and MUC2 expression (P=0.008). Univariate analysis identified that poor patient survival was significantly associated with histological grade (P=0.020), invasion depth (P=0.005), lymph node metastasis (P=0.012), tumor stage (P=0.004) and vessel invasion (P=0.023). The tumor stage (P=0.002) was a poor independent prognostic indicator, while MUC6 expression (P=0.036) was a good independent prognostic indicator. The survival rate in patients with K20-positive ICC was lower compared to that of patients with K20-negative ICC, but was not statistically significant. Furthermore, the combined K7/K20 immunophenotype was identified to be useful for differentiating ICC and metastatic CRC. K20-positive ICC displays specific characteristics with regards to tumor location and histological subtype. Additionally, MUC6 expression in ICC is a good independent prognostic factor, while K20 expression is more often associated with aggressive biological behavior.

Entities:  

Year:  2012        PMID: 22970052      PMCID: PMC3439098          DOI: 10.3892/ol.2012.756

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  28 in total

1.  Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct--an immunohistochemical study of 110 cases of hepatolithiasis.

Authors:  Yoh Zen; Motoko Sasaki; Takahiko Fujii; Tse-Ching Chen; Miin-Fu Chen; Ta-Sen Yeh; Yi-Yin Jan; Shiu-Feng Huang; Yuji Nimura; Yasuni Nakanuma
Journal:  J Hepatol       Date:  2005-12-05       Impact factor: 25.083

2.  The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver.

Authors:  T Maeda; K Kajiyama; E Adachi; K Takenaka; K Sugimachi; M Tsuneyoshi
Journal:  Mod Pathol       Date:  1996-09       Impact factor: 7.842

3.  Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.

Authors:  M Higashi; S Yonezawa; J J Ho; S Tanaka; T Irimura; Y S Kim; E Sato
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

4.  Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis.

Authors:  A Rullier; B Le Bail; R Fawaz; J F Blanc; J Saric; P Bioulac-Sage
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

5.  Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma.

Authors:  Naoki Matsumura; Masakazu Yamamoto; Atsushi Aruga; Ken Takasaki; Masayuki Nakano
Journal:  Cancer       Date:  2002-03-15       Impact factor: 6.860

Review 6.  Biliary papillary neoplasm of the liver.

Authors:  Y Nakanuma; M Sasaki; A Ishikawa; W Tsui; T C Chen; S F Huang
Journal:  Histol Histopathol       Date:  2002       Impact factor: 2.303

Review 7.  Cytokeratin markers come of age.

Authors:  Stig Linder
Journal:  Tumour Biol       Date:  2007-08-23

8.  Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.

Authors:  Takahiro Uenishi; Osamu Yamazaki; Hiromu Tanaka; Shigekazu Takemura; Takatsugu Yamamoto; Shogo Tanaka; Shuhei Nishiguchi; Shoji Kubo
Journal:  Ann Surg Oncol       Date:  2007-10-23       Impact factor: 5.344

9.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies.

Authors:  R Moll; A Löwe; J Laufer; W W Franke
Journal:  Am J Pathol       Date:  1992-02       Impact factor: 4.307

10.  Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact.

Authors:  Sin Young Park; Sang Jae Roh; Yo Na Kim; Sung Zoo Kim; Ho Sung Park; Kyu Yun Jang; Myoung Ja Chung; Myoung Jae Kang; Dong Geun Lee; Woo Sung Moon
Journal:  Oncol Rep       Date:  2009-09       Impact factor: 3.906

View more
  1 in total

Review 1.  Review to better understand the macroscopic subtypes and histogenesis of intrahepatic cholangiocarcinoma.

Authors:  Yuichi Sanada; Yujo Kawashita; Satomi Okada; Takashi Azuma; Shigetoshi Matsuo
Journal:  World J Gastrointest Pathophysiol       Date:  2014-08-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.